Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927341 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01927341 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 53 participants.
The verdict
NCT01927341, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
Interventions
- DRUG Panitumumab
- DRUG MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2013-11-19 |
| Est. Completion | 2016-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927341
The ClinicalTrials.gov registry entry for NCT01927341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panitumumab is the first listed.
NCT01927341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927341 about?
NCT01927341 is a clinical study titled "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors". The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
What is the current status of trial NCT01927341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2013-11-19. Estimated completion is 2016-01-25.
What interventions are being tested in trial NCT01927341?
The interventions under investigation include: Panitumumab (DRUG), MEK162 (DRUG).
Who is sponsoring clinical trial NCT01927341?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.